GlassScriptPhysician profile
Brittany Venable
NPI 1376913210
$1,550.33
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $496 · 2023: $523 · 2024: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.89 | 2021-2024 | |
| Lilly USA, LLC | $307.03 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $182.10 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $60.12 | 2022-2024 | Austedo, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $51.45 | 2022 | |
| Abbott Laboratories | $50.43 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $41.56 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $38.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.87 | 2022-2024 | |
| Biogen, INC. | $32.50 | 2024 | Skyclarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.33 | 2023-2024 | Xifaxan |
| Acerus Pharmaceuticals Corporation | $28.11 | 2022 | |
| Halozyme INC | $23.74 | 2023 | |
| Janssen Pharmaceuticals, INC | $20.27 | 2023 | Xarelto |
| Shield Therapeutics INC | $19.51 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.87 | 2024 | Eliquis |
| Antares Pharma, INC. | $15.02 | 2023 | Nocdurna, Tlando, Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $13.97 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.94 | 2024 | Farxiga |
| Noven Therapeutics, LLC | $12.91 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Venable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.